Glutide for Ending Methamphetamine

GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD. The second phase will be a phase IIb randomized-controlled trial to determine the efficacy of Wegovy in treating MeUD. This trial will be similar to the pilot with randomization to Wegovy or placebo and blinding of group assignment. The trial will enroll 162 participants across two sites.

NCT Number	NCT07204249
Lead Sponsor	San Francisco Department of Public Health
Conditions	Methamphetamine-dependence
Enrollment	162 participants
Start Date	2026-02-26
Primary Completion	2030-02-15 (estimated)
Study Completion	2030-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-06-03